These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 24055428

  • 1. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 2. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

  • 3. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators.
    Eur Urol; 2017 Feb 15; 71(2):281-289. PubMed ID: 27726966
    [Abstract] [Full Text] [Related]

  • 4. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3020-6. PubMed ID: 23720197
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
    Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan 15; 32(1):30.e15-21. PubMed ID: 23428534
    [Abstract] [Full Text] [Related]

  • 6. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
    Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G.
    BJU Int; 2014 May 15; 113(5b):E137-43. PubMed ID: 24219029
    [Abstract] [Full Text] [Related]

  • 7. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
    Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S, Murai S, Shinohara N.
    Urol Oncol; 2017 Feb 15; 35(2):38.e1-38.e8. PubMed ID: 27693091
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
    Jessen C, Agerbaek M, Von Der Maase H.
    Acta Oncol; 2009 Feb 15; 48(3):411-7. PubMed ID: 18798018
    [Abstract] [Full Text] [Related]

  • 9. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
    Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH.
    Int J Urol; 2016 May 15; 23(5):385-9. PubMed ID: 26992082
    [Abstract] [Full Text] [Related]

  • 10. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC, Hsu CH, Huang CY, Tsai YC, Huang KH, Cheng AL, Pu YS.
    Urology; 2007 Mar 15; 69(3):479-84. PubMed ID: 17382149
    [Abstract] [Full Text] [Related]

  • 11. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2013 Sep 15; 11(3):346-52. PubMed ID: 23673281
    [Abstract] [Full Text] [Related]

  • 12. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
    Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, Dimopoulos MA, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguié M, Rouprêt M, French Collaborative National Database on UUT-UCC.
    Cancer; 2011 Dec 15; 117(24):5500-8. PubMed ID: 21638278
    [Abstract] [Full Text] [Related]

  • 13. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.
    Clin Genitourin Cancer; 2016 Jun 15; 14(3):255-60. PubMed ID: 26552764
    [Abstract] [Full Text] [Related]

  • 14. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    Sonpavde G, Watson D, Tourtellott M, Cowey CL, Hellerstedt B, Hutson TE, Zhan F, Vogelzang NJ.
    Clin Genitourin Cancer; 2012 Mar 15; 10(1):1-5. PubMed ID: 22340630
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 16. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world.
    Taguchi S, Nakagawa T, Uemura Y, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Fujimura T, Fukuhara H, Kume H, Homma Y.
    World J Urol; 2016 Feb 15; 34(2):163-71. PubMed ID: 26135306
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
    Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y.
    Int J Urol; 2015 Jul 15; 22(7):638-43. PubMed ID: 25903328
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer.
    Sengeløv L, Kamby C, Geertsen P, Andersen LJ, von der Maase H.
    Cancer Chemother Pharmacol; 2000 Jul 15; 46(5):357-64. PubMed ID: 11127939
    [Abstract] [Full Text] [Related]

  • 19. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
    Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K.
    Eur Urol; 2007 Oct 15; 52(4):1106-13. PubMed ID: 17367917
    [Abstract] [Full Text] [Related]

  • 20. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.